Nuvectis Pharma, Inc. NVCT
Nuvectis Pharma, Inc. (Nasdaq: NVCT) is an immunology/inflammation drug developer. Its lead program, NXP100 (ciprocopan), is in Phase 3 for complement-related conditions (PNH, IgAN, C3G, LN, MG, d-AMD). Its next catalyst on record is NXP100: Marketing application decision for previously treated PNH in China (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NXP100 — Marketing application decision for previously treated PNH in China (date not stated). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NXP100 (ciprocopan) | PNH (paroxysmal nocturnal hematoglobinuria) | small molecule | Approved |
| NXP100 (ciprocopan) | IgA Nephropathy | small molecule | Phase 3 |
| NXP100 (ciprocopan) | lupus nephritis | small molecule | Phase 2 |
| NXP200 (HSK42360) | BRAF V600-mutated high-grade glioma | small molecule | Phase 1 |
| NXP200 (HSK42360) | BRAF V600-mutated low-grade glioma | small molecule | Phase 1 |
| NXP900 | combination with osimertinib (EGFR-mutant NSCLC) | small molecule | Phase 1 |
| NXP900 | combination with lorlatinib (ALK-positive cancer) | small molecule | Phase 1 |
| NXP900 | combination with daraxonrasib in pancreatic cancer | small molecule | Phase 1 |
| NXP800 | ovarian cancer | small molecule | Phase 1 |
Recent results and decisions
- Nov 4, 2026submitted Second marketing application for ciprocopan in China under review for PNH patients previously treated with anti-C5 therapy, with approval expected in Q1 2027.
A second marketing application for ciprocopan in China is currently under review, for the treatment of PNH patients previously treated with anti C5 therapy, with approval expected in 1Q27.
Filing - Jul 1, 2026approval Ciprocopan approved in China for treatment of PNH patients previously untreated with complement inhibitors.
In July 2026, ciprocopan achieved its first global approval (in China), for the treatment of patients with PNH previously untreated with complement inhibitors.
Filing - May 4, 2026positive Phase 1b data for NXP200 showed 40% ORR in high-grade glioma and 42.9% in low-grade glioma including complete responses.
Treatment with NXP200 resulted in an ORR of 40.0% in the high-grade glioma cohort, including 3 CRs (two confirmed and one preliminary) and 42.9% in the low-grade glioma cohort, including one confirmed CR.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
- Sanofi SNY
- Argenx SE ARGX
- Roivant Sciences Ltd. ROIV
- Immunovant, Inc. IMVT
- Celldex Therapeutics, Inc. CLDX
- Biohaven Ltd. BHVN
- BioCryst Pharmaceuticals, Inc. BCRX
- Zenas BioPharma ZBIO
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.